Dr. Goggins’ current research is focused on discovering new markers of pancreatic adenocarcinoma using genetic, epigenetic and proteomic strategies, characterizing the epigenetic alterations in pancreatic cancers and normal tissues and identifying familial pancreatic cancer susceptibility genes through linkage, genome wide association and candidate gene approaches. Additional epigenetic studies are aimed at determining the functional and clinical significance of aberrant DNA methylation changes in pancreatic cancers.
In the Pancreatic Cancer Early Detection Laboratory, Dr. Goggins oversees research that focuses on gene expression patterns of pancreatic cancers using microarray technology. The lab is also studying DNA methylation patterns looking for genes that are methylated in pancreatic cancer but not in normal cells.
The lab has put together a profile of genes that are methylated in pancreatic cancer. Some pancreatic cancers methylate a lot of genes; most appear to methylate only a few genes. The lab is currently directing efforts to identify additional genes methylated in pancreatic cancer using novel techniques, and is studying the role of telomerase in pancreatic cancer and its potential as a marker for early detection.
Lab Website: Early Detection of Pancreatic Cancer Laboratory
The Cancer of the Pancreas Screening-5 CAPS5)Study
View all on PubMed
Tamura K, Yu J, Hata T, Suenaga M, Shindo K, Abe T, MacGregor-Das A, Borges M, Wolfgang CL, Weiss MJ, He J, Canto MI, Petersen GM, Gallinger S, Syngal S, Brand RE, Rustgi A, Olson SH, Stoffel E, Cote ML, Zogopoulos G, Potash JB, Goes FS, McCombie RW, Zandi PP, Pirooznia M, Kramer M, Parla J, Eshleman JR, Roberts NJ, Hruban RH, Klein AP, Goggins M: Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 2018, 115:4767-72
Abe T, Blackford AL, Tamura K, Ford M, McCormick P, Chuidian M, Almario JA, Borges M, Lennon AM, Shin EJ, Klein AP, Hruban RH, Canto MI, Goggins M: Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. J Clin Oncol 2019, 37:1070-80
Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, Kitaoka N, Chuidian M, Ford M, Dbouk M, Borges M, He J, Burkhart R, Wolfgang CL, Klein AP, Eshleman JR, Hruban RH, Canto MI, Goggins M: Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 2020, 18:1161-9.e5. doi: 10.016/j.cgh.2019.10.036. Epub Oct 30
Blackford AL, Canto MI, Klein AP, Hruban RH, Goggins M: Recent trends in the incidence and survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results analysis. J Natl Cancer Inst 2020, 112:1162-9
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M: Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020, 69:7-17. doi: 0.1136/gutjnl-2019-319352. Epub 2019 Oct 31